Completes the Acquisition of Galil Medical

BTG completes the acquisition of Galil Medical

London, UK, 15 June 2016: BTG plc (LSE: BTG), the specialist healthcare company, is pleased to announce that it has completed the acquisition of Galil Medical, a leading provider of cryoablation products for the treatment of kidney and other cancers.

BTG announced on 6 May 2016 that it had entered into an agreement to acquire Galil.

For further information contact:

BTG

Andy Burrows, VP Corporate & Investor Relations

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director

+44 20 7575 1595; Mobile: +44 7773 251 178

FTI Consulting

Ben Atwell/Simon Conway

+44 (0)20 3727 1000

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, advanced emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com